Dr. Reddy's Laboratories launch of Memantine hydrochloride tablets USP in US market

Dr. Reddy's Laboratories (NYSE: RDY) has launched Memantine hydrochloride tablets USP, 5 mg and 10 mg, a therapeutic equivalent generic version of NAMENDA® (memantine HCl) tablets in the US market on July 12, 2015, approved by the United States Food & Drug Administration (USFDA).

The NAMENDA® (memantine HCl) tablets brand had U.S. sales of approximately $ 1.4 Billion MAT for the most recent twelve months ending in May 2015 according to IMS Health*.

Dr. Reddy's Memantine hydrochloride tablets USP, 5 mg is available in bottle count size of 60 and the Memantine hydrochloride tablets USP, 10 mg are available in bottle count sizes of 60 and 500.

NAMENDA® is a registered trademark of Merz Pharma GmbH & Co. KGaA

*IMS National Sales Perspectives: Retail and Non-Retail MAT May 2015

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.3758.75 as compared to the previous close of Rs. 3742.15. The total number of shares traded during the day was 18412 in over 1949 trades.

The stock hit an intraday high of Rs. 3785.9 and intraday low of 3725.65. The net turnover during the day was Rs. 69261174.

Source : Equity Bulls

Keywords